Drug Type Gene editing |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Egret Therapeutics, Inc.Startup |
Active Organization Egret Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Ischemia | Phase 2 | US | Egret Therapeutics, Inc.Startup | 06 Feb 2023 |
Ischemic stroke | Preclinical | US | Egret Therapeutics, Inc.Startup | 06 Feb 2023 |